Research on Aptamer Group Plc (APTA:LON) from Turner Pope Investments
Aptamer Group PLC has announced a research collaboration with Pharmahungary Group to develop Optimer® delivery vehicles targeting heart and skeletal muscle, structured on a cost-sharing basis where each party funds its own work and retains its intellectual property. Pharmahungary Group will conduct preclinical studies, which would typically cost between £300,000 and £500,000, without requiring Aptamer to incur unbudgeted expenditure or alter its cash runway projections. Aptamer will retain full ownership of its Optimer® delivery vehicles and associated IP, while owning 50% of the combined Optimer®-miRNA therapeutic. This partnership aims to generate preclinical data for future licensing opportunities in the growing oligonucleotide therapeutics market, forecast to reach US$17.7 billion by 2030.
View Full Research